Lundbeck
Lundbeck, officially known as H. Lundbeck A/S, is a global pharmaceutical company headquartered in Denmark (DK). Founded in 1915, Lundbeck has established itself as a leader in the neuroscience sector, focusing on the treatment of brain disorders such as depression, schizophrenia, and Alzheimer's disease. With a strong presence in Europe, North America, and Asia, the company is dedicated to improving the lives of patients through innovative therapies. Lundbeck's core products include a range of unique medications that address complex neurological conditions, setting them apart in a competitive market. The company has achieved notable milestones, including the development of several breakthrough treatments that have significantly impacted patient care. Renowned for its commitment to research and development, Lundbeck continues to strengthen its position as a key player in the global pharmaceutical industry.
DitchCarbon Score
How does Lundbeck's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Lundbeck's score of 78 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Lundbeck's reported carbon emissions
In 2023, H. Lundbeck A/S reported total greenhouse gas emissions of approximately 119,336,000 kg CO2e, with emissions distributed across various scopes: 11,314,000 kg CO2e from Scope 1, 1,845,000 kg CO2e from Scope 2, and 119,336,000 kg CO2e from Scope 3. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050. Lundbeck's near-term targets include a 42% reduction in absolute Scope 1 and 2 emissions by 2029, using 2019 as the base year. Additionally, the company aims to reduce Scope 3 emissions from purchased goods and services, upstream transportation and distribution, and business travel by 25% within the same timeframe. For the long term, Lundbeck has committed to a 90% reduction in absolute emissions across all scopes by 2050, again using 2019 as the baseline. These targets align with the Science Based Targets initiative (SBTi) and reflect Lundbeck's commitment to sustainable practices within the pharmaceutical industry, demonstrating a proactive approach to addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Lundbeck is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
